HeartBeam

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

HeartBeam reports Q1 loss, eyes FDA clearances for growth

HeartBeam's Q1 2024 performance showed financial challenges but promising technological advancements
The company's focus on FDA clearances and AI development positions it for growth
Opportunities in remote cardiac monitoring and AI-driven healthcare present avenues for expansion
Balancing financial stability with innovation will be key for HeartBeam's future success

HeartBeam advances AIMIGo technology despite financial challenges

HeartBeam is making progress towards FDA clearance for its innovative cardiac monitoring device, AIMIGo.
Despite financial challenges, the company's strong IP protection and AI capabilities position it well for future growth.
Opportunities lie in expanding technology applications, gaining regulatory approval, and leveraging AI for automated diagnostics.

HeartBeam reports Q3 loss, progresses FDA review, and strengthens leadership

HeartBeam's Q3 2024 financials show a net loss of $4.979 million, with a focus on managing cash burn and aligning capital raising with milestones.
The company's core technology and clinical evidence position it well for FDA clearances and commercial launch preparations.
New management appointments bring leadership strength to drive HeartBeam's growth and innovation in cardiac care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

cquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with an Existing Cutting Edge FDA-Cleared Product, Halo+™ Atrial Fibrillation Detection System

HeartBeam Reports Fourth Quarter and Full Year 2022 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today announced the strategic acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical physiological biomarkers. The acquisition extends HeartBeam's reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product.

HeartBeam Announces Acquisition of LIVMOR Assets

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has announced a senior leadership change ahead of key milestones in 2023 including FDA clearance for the HeartBeam AIMI™ system and FDA submission of the HeartBeam AIMIGo™ 3D vector ECG first generation product. HeartBeam President Robert Eno will be assuming the duties and responsibilities of Executive Vice President and Chief Business Officer Jon Hunt, Ph.D., who will be stepping down from his current position and transitioning to the role of strategic advisor and consultant for the Company, effective March 15, 2023.

HeartBeam Announces Senior Leadership Change

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, will hold a conference call on Thursday March 16, 2023 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2023 milestones. A press release detailing these results will be issued prior to the call.

HeartBeam to Host Fourth Quarter and Full Year 2022 Results Conference Call on Thursday March 16, 2023 at 4:30 p.m. Eastern Time

The company's products, HeartBeam AIMI and HeartBeam AIMIGo, are being developed with the aim of providing accurate diagnostic tools for heart attack detection anytime and anywhere. The core technology is protected by a strong and expanding IP portfolio comprising multiple patents.

HeartBeam Inc. - Developing Heart Attack Detection Diagnostic Technology With Remote Monitoring Capabilities

SANTA CLARA, Calif.--( BUSINESS WIRE )--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced today the appointment of Robert Eno to the newly created position of President. Eno has a proven track record of developing markets and commercializing disruptive medical technologies. He will play a key role in the strategic direction, commercialization efforts, and day-to-day operations for the HeartBeam AIMI™ and HeartBeam AIMIGo™ platforms.

HeartBeam Appoints Robert Eno as President

NEW YORK, NY / ACCESSWIRE / January 12, 2023 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Heartbeam. Toni had the pleasure of recently conducting the Interview with Branislav Vajdic, PhD CEO & Founder of Heartbeam Inc. (NASDAQ:BEAT).

CEO & Founder of Heartbeam Inc. Discusses the Potential for the AIMI(TM) and AIMIGo(TM) Technology in an Audio Interview with TradersNewsSource.com

SANTA CLARA, Calif.--( BUSINESS WIRE )--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the European Patent Office. This patent offers protection for HeartBeam's flagship technology in multiple countries in Europe and has been validated in France, Germany, Netherlands and the United Kingdom. The innovation opens the pathway for a patient to record a set of signals using HeartBeam AIMIGo outside of a medical setting with a diagnostic synthesized 12-lead ECG immediately transmitted to a physician for review and diagnosis.

HeartBeam Granted European Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

SANTA CLARA, Calif.--( BUSINESS WIRE )--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today issued a letter to shareholders from its Chief Executive Officer and Founder, Branislav Vajdic, PhD.

HeartBeam Issues Shareholder Letter and Provides Corporate Update

I can only give HeartBeam a hold rating. This cardiac technology firm's stock has risen too much recently. BEAT's 3-month price performance is +349.22%. I think investors should take profit now because its product still has no FDA approval. Zero revenue until now.

Cash Out Or Hold On To HeartBeam?

SANTA CLARA, Calif.--( BUSINESS WIRE )--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today announced it has signed an agreement (the “Agreement”) with Evolve Manufacturing Technologies (“Evolve”), a contract medical device manufacturing company, to build the credit card-sized AIMIGo 3D vector electrocardiogram (VECG) recording device that provides a 12 lead ECG readout for remote heart attack detection. Under the terms of the Agreement, HeartBeam will leverage Evolve's manufacturing and packaging expertise to support commercialization of the HeartBeam AIMIGo device in anticipation of early market testing in Q2 2023 following expected FDA Clearance in early 2023.

HeartBeam Partners with Evolve Manufacturing to Build HeartBeam AIMIGoTM 12-Lead 3D Vector Electrocardiogram Device

SANTA CLARA, Calif.--( BUSINESS WIRE )--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced today that its patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended for detection of heart attacks and complex cardiac arrhythmias was allowed by the United States Patent and Trademark Office. The innovation builds on HeartBeam's growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting.

New HeartBeam Patent for 12-Lead Electrocardiogram (ECG) Smartwatch-based Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias

HeartBeam, Inc. (NASDAQ:BEAT ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Branislav Vajdic – Founder and Chief Executive Officer Jon Hunt – Chief Business Officer Rick Brounstein – Chief Financial Officer Conference Call Participants Jason Kolbert – Dawson James Bill Sutherland – The Benchmark Company Operator Greetings, and welcome to the HeartBeam Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

HeartBeam, Inc. (BEAT) Q3 2022 Earnings Call Transcript

SANTA CLARA, Calif.--( BUSINESS WIRE )--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has reported its financial and operational results for the third quarter ended September 30, 2022.

HeartBeam Reports Third Quarter 2022 Financial Results

HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern Time

Akero Therapeutics Inc

Astria Therapeutics

ContraFect

Humanigen

Otonomy

Rhythm Pharmaceuticals

Vigil Neuroscience

Virios Therapeutics

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

Applied DNA Sciences

Avenue Therapeutics

Immuneering Corp

Mind Medicine MindMed

PhaseBio Pharmaceuticals Inc

Shuttle Pharmaceuticals Holdings Inc

Spero Therapeutics

September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

Greenwich Lifesciences

Aerovate Therapeutics

Minerva Neurosciences

Virgin Orbit Holdings

Short-squeeze stocks continue to be a big deal for speculative traders and we're helping them out with a list to keep in mind this week! That list comes from Fintel and its Short Squeeze Leaderboard.

GLSI, AVTE: The Top 5 Short Squeeze Stocks to Watch This Week

HeartBeam to Present at LD Micro Main Event XV Conference

SEOUL, South Korea--(BUSINESS WIRE)---- $BEAT #ACCapital--GSR and GBIC invest in MetaBeat, a web3 music NFT and SocialFi platform.

Music NFT and SocialFi Platform, MetaBeat Attracts Investments From Top Global Crypto Funds

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

Source: shutterstock.com/Anastasia Zagoruyko HeartBeam (NASDAQ: BEAT ) stock is seeing gains on Thursday as investors react to news of it expanding its product portfolio pipeline. That expansion has the company working to develop arrhythmia detection capabilities.

Why Is HeartBeam (BEAT) Stock Up 24% Today?

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Broadens Product Portfolio Pipeline with Smartwatch Connectivity Enablement for 24/7 Heart Monitoring Solution

HeartBeam Broadens Product Portfolio Pipeline with Smartwatch Connectivity Enablement for 24/7 Heart Monitoring Solution

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Present at Upcoming Investor Conferences

HeartBeam to Present at Upcoming Investor Conferences

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Granted Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam Granted Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

News for HeartBeam Stock (BEAT)